Investor Presentaiton

Drive 2.0 (FY2023-2025) Targets Medical Business SEKISUI ■ Accelerate growth centered on the Overseas Diagnostics Business through expansion in diagnostics fields and by increasing new product sales; continue to achieve record-high profit Create new businesses; strengthen R&D Net Sales (JPY billion) 72.6 89.7 Analysis of Operating Profit (JPY billion) +22.8 Consoli- dated- basis Change Diagno- Foreign stics Exchange (Japan) Diagno- Pharmaceutical stics Science and (overseas) Other Fixed Costs Total 112.5 Deference +0.1 0 +1.9 (+10.6) +1.5 -8.7 +5.5 18.0 +5.5 12.5 FY2022 FY2019 Results FY2022 Results FY2025 Medium-term Plan Results Copyright SEKISUI CHEMICAL CO., LTD. FY2025 Medium-term Plan 40

View entire presentation